Literature DB >> 10861433

Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age.

N S Goldstein1, F A Vicini, L L Kestin, M Thomas.   

Abstract

BACKGROUND: Young patient age at diagnosis has been reported as a risk factor for recurrence in patients with ductal carcinoma in situ (DCIS) of the breast treated with breast-conserving therapy (BCT). The authors examined pathologic features of DCIS in three different age groups of patients to identify differences that might explain why young patient age at the time of diagnosis is a risk factor for recurrence.
METHODS: Excised specimens from 177 breasts of 172 patients with DCIS treated with BCT were studied. All slides from all specimens were reviewed. Patients were divided into 3 age groups: those age < 45 years, those ages 45-59 years, and those age >/= 60 years. The histologic features that were quantified included most common and highest nuclear grades, DCIS architectural pattern, amount of central necrosis (quartiles), calcifications, amount of DCIS, and number of terminal duct lobular units (TDLUs) with cancerization of lobules (COL) within 0.42 cm of the margin, margin status, and size and volume of excision specimens.
RESULTS: Patients age < 45 years at the time of diagnosis more frequently had higher nuclear grade DCIS (highest nuclear Grade 3: 69%, 60%, and 39%; P = 0.003), respectively and central necrosis (72%, 62%, and 44%; P = 0. 01), respectively. Although not statistically significant, younger patients tended to have comedo subtype DCIS more often (31%, 23%, and 19%; P = 0.35), respectively. Younger patients also more often had smaller initial biopsy specimen maximum dimensions (4.3 cm, 5.2 cm, and 5.7 cm; P = 0.004), respectively, with close or positive margins (89%, 61%, and 64%; P = 0.03), and more TDLUs with COL in the 0.42-cm rim of tissue adjacent to the margin (5.2, 3.6, and 1.9; P = 0.23), respectively. No other features including the amount of DCIS when classified as > 50% or > 75% of ducts, calcifications within DCIS ducts, pattern of DCIS involvement, number of slides examined, number of slides with DCIS, and mean number of DCIS ducts near the margin were found to occur more frequently in younger patients.
CONCLUSIONS: Younger patients with DCIS may have an increased risk of local recurrence when treated with BCT due to smaller initial excision volumes, a greater proportion of high nuclear grade DCIS, and central necrosis. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10861433     DOI: 10.1002/1097-0142(20000601)88:11<2553::aid-cncr18>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Clinicopathological features and prognosis of pregnancy associated breast cancer - a matched case control study.

Authors:  Lilla Madaras; Kristóf Attila Kovács; Attila Marcell Szász; István Kenessey; Anna-Mária Tőkés; Borbála Székely; Zsuzsanna Baranyák; Orsolya Kiss; Magdolna Dank; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2013-12-20       Impact factor: 3.201

2.  HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.

Authors:  I E Krop; D Sgroi; D A Porter; K L Lunetta; R LeVangie; P Seth; C M Kaelin; E Rhei; M Bosenberg; S Schnitt; J R Marks; Z Pagon; D Belina; J Razumovic; K Polyak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

3.  Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.

Authors:  Megan E Tesch; Shoshana M Rosenberg; Laura C Collins; Julia S Wong; Laura Dominici; Kathryn J Ruddy; Rulla Tamimi; Lidia Schapira; Virginia F Borges; Ellen Warner; Steven E Come; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2022-08-12       Impact factor: 4.339

4.  Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.

Authors:  Laura C Collins; Ninah Achacoso; Larissa Nekhlyudov; Suzanne W Fletcher; Reina Haque; Charles P Quesenberry; Balaram Puligandla; Najeeb S Alshak; Lynn C Goldstein; Allen M Gown; Stuart J Schnitt; Laurel A Habel
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

5.  Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS).

Authors:  Jérôme Toussaint; Virginie Durbecq; Sevilay Altintas; Valérie Doriath; Ghizlane Rouas; Marianne Paesmans; Philippe Bedard; Benjamin Haibe-Kains; Wiebren A Tjalma; Denis Larsimont; Martine Piccart; Christos Sotiriou
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

6.  Breast cancer in Chinese women younger than age 40: are they different from their older counterparts?

Authors:  Ava Kwong; Polly Cheung; Stephanie Chan; Silvia Lau
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

Review 7.  Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).

Authors:  Bo-Rim Yi; Kelvin J Choi; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Oncol       Date:  2012-06-20       Impact factor: 5.650

Review 8.  Current view on ductal carcinoma in situ and importance of the margin thresholds: A review.

Authors:  A Van Cleef; S Altintas; M Huizing; K Papadimitriou; P Van Dam; W Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2014

9.  Predicting invasive breast cancer versus DCIS in different age groups.

Authors:  Mehmet U S Ayvaci; Oguzhan Alagoz; Jagpreet Chhatwal; Alejandro Munoz del Rio; Edward A Sickles; Houssam Nassif; Karla Kerlikowske; Elizabeth S Burnside
Journal:  BMC Cancer       Date:  2014-08-11       Impact factor: 4.430

Review 10.  The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ.

Authors:  Peter T Simpson; Theodora Gale; Laura G Fulford; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2003-07-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.